Napoleone Ferrara
CIK: 0001744779
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Kalaris Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jun 3, 2026KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
9K shares- - Apr 10, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - Mar 18, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)Direct504K shares-
1-3 of 3 transactions
About Ferrara Napoleone
Ferrara Napoleone (SEC CIK 0001744779) files insider reports with the SEC as Director of Kalaris Therapeutics, Inc. (KLRS).
Signal8 holds 4 ownership filings by Ferrara Napoleone (1 Form 3, 3 Form 4), filed between Mar 18, 2025 and Jun 4, 2026. Those filings report 3 transactions, from Mar 18, 2025 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ferrara Napoleone's filings is in BERKELEY HEIGHTS, NJ.
Recent filings by Ferrara Napoleone
Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)
- Vandekop Amy O'Leary, VP, Corporate Controller
- KEATING LAURIE, Director
- Bayko Liisa Ann, Chief Financial Officer
- Jovan-Embiricos Morana, Director
- Hallal David, Director
- AKKARAJU SRINIVAS, Director